Clinical trials: sponsored by Merck Sharp & Dohme LLC
Colorectal Cancer
A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer
This study is being done to test the safety and effectiveness of the combination of intravenous (IV) romidepsin and/or oral 5-azacitidine with IV MK-3475 in people with microsatellite stable (MSS) advanced colorectal cancer.
- Trial name
- NCT02512172
- Testing
- Oral CC-486, Romidepsin, MK-3475
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Endometrial Neoplasms
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study
The purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma.
- Trial name
- LEAP-001 (NCT04865289)
- Testing
- Lenvatinib, Pembrolizumab, Paclitaxel
- Where
- 22 sites in China
- Volunteers
- 130 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer
Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab
Soft tissue sarcomas represent a subtype of cancer that is both rare and very heterogeneous. When they are organized, their current treatment is essentially based on tumor resection surgery, +/- associated with treatment by…
- Trial name
- NeoSarc (NCT06116578)
- Testing
- Pembrolizumab, Pembrolizumab and Olaparib, Pembrolizumab adjuvant
- Where
- France
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Advanced Head and Neck Squamous Cell Carcinoma, Advanced Breast Cancer
A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers
This Phase 1b/2a study will assess the efficacy, safety, and pharmacodynamics of CyPep-1 when administered directly into measurable tumor lesions in combination with the anti-PD-1 antibody pembrolizumab.
- Conditions
- Advanced Head and Neck Squamous Cell Carcinoma, Advanced Breast Cancer, Advanced Melanoma
- Trial name
- Catalyst (NCT05383170)
- Testing
- CyPep-1, Pembrolizumab 25 MG/ML [KEYTRUDA®]
- Where
- 25 sites in United States, France and 3 more
- Volunteers
- 6 people
- Sponsor
- Cytovation AS
Small Cell Ovarian Carcinoma
Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT
Small cell ovarian carcinomas are rare and have a very poor prognosis affecting a young population. The objective of this study is to increase the efficacy of the initial chemotherapy by providing immunotherapy and to be able to…
- Trial name
- PembroSCCOHT (NCT04602377)
- Testing
- Pembrolizumab 25 MG/ML [Keytruda]
- Where
- 13 sites in France
- Volunteers
- 27 people
- Sponsor
- ARCAGY/ GINECO GROUP
Melanoma
BO-112 With Pembrolizumab in Unresectable Malignant Melanoma
This is a phase 2, single arm, open label, adaptive design study to determine the preliminary anti-tumor activity and confirm the safety of IT BO-112 in combination with intravenous (IV) pembrolizumab.
- Trial name
- SPOTLIGHT203 (NCT04570332)
- Testing
- BO-112 plus pembrolizumab, Tissue Biopsies
- Where
- 19 sites in France, Spain
- Volunteers
- 42 people
- Sponsor
- Highlight Therapeutics
Colorectal Cancer
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study
The purpose of this China extension study is to assess the safety and efficacy of coformulated favezelimab/pembrolizumab (MK-4280A) in adult Chinese participants with metastatic colorectal cancer.
- Trial name
- NCT05600309
- Testing
- favezelimab/pembrolizumab, regorafenib, TAS-102
- Where
- 24 sites in China
- Volunteers
- 94 people
- Sponsor
- Merck Sharp & Dohme LLC
Respiratory Tract Infections (RTI), Lower Respiratory Tract Infection (LRTI)
Respiratory Infections in Young Children
The goal of this observational study is to learn about the causes, severity, and long-term effects of respiratory tract infections (RTIs) in young children from birth to five years of age in Colombia and Panamá.
- Conditions
- Respiratory Tract Infections (RTI), Lower Respiratory Tract Infection (LRTI), Viral Infections, Cohort Study
- Trial name
- MINERVAL (NCT07249996)
- Where
- 2 sites in Colombia, Panama
- Volunteers
- 1,088 people, healthy volunteers welcome
- Sponsor
- Eduardo Lopez -Medina
Metastatic Cancer, Soft Tissue Sarcoma
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of BT-001 with repeated IT administrations alone and in combination with IV infusions of pembrolizumab.
- Conditions
- Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma
- Trial name
- NCT04725331
- Testing
- BT-001, Pembrolizumab [KEYTRUDA®]
- Where
- 5 sites in Belgium, France
- Volunteers
- 31 people
- Sponsor
- Transgene
HIV-1 Infection
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)
The primary objectives of this study are to evaluate the safety and tolerability of a switch to Doravirine/Islatravir (DOR/ISL) compared with continued baseline antiretroviral therapy (ART), through Week 48; and to evaluate the…
- Trial name
- NCT05631093
- Testing
- ART, DOR/ISL
- Where
- 53 sites in United States, Australia and 6 more
- Volunteers
- 553 people
- Sponsor
- Merck Sharp & Dohme LLC
Pancreatic Cancer
Cabozantinib and Pembrolizumab in Metastatic Pancreas
This study aims to evaluate cabozantinib and pembrolizumab for the treatment of metastatic pancreatic adenocarcinoma.
- Trial name
- NCT05052723
- Testing
- Cabozantinib, Pembrolizumab
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Joseph Kim
Metastatic Clear Cell Renal Cell Carcinoma, Recurrent Clear Cell Renal Cell Carcinoma
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
This phase II trial studies how well pembrolizumab with or without standard of care axitinib works in treating patients with clear cell kidney cancer that has spread to nearby tissues or lymph nodes (locally advanced) or other…
- Conditions
- Metastatic Clear Cell Renal Cell Carcinoma, Recurrent Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Trial name
- NCT04370509
- Testing
- Axitinib (VEGF-TKI), Cytoreductive Nephrectomy (CN), Metastasectomy (MET)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Francisco
Breast Cancer, Non-small Cell Lung Carcinoma
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
This two-part study will include a dose escalation part to determine the recommended dose for expansion of DS8201a and pembrolizumab and a dose expansion part to evaluate efficacy, safety, and tolerability of the combination.
- Trial name
- NCT04042701
- Testing
- Trastuzumab deruxtecan (DS-8201a), Pembrolizumab
- Where
- 30 sites in United States, France and 2 more
- Volunteers
- 115 people
- Sponsor
- Daiichi Sankyo
HIV-1 Infection
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
The primary objectives of this study are to evaluate the antiretroviral activity of a switch to Doravirine/Islatravir (DOR/ISL) compared with continued Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) at Week 48; and…
- Trial name
- NCT05630755
- Testing
- DOR/ISL, BIC/FTC/TAF
- Where
- 49 sites in United States, Australia and 4 more
- Volunteers
- 514 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer
Window of Opportunity Study in Colorectal Cancer
This is a window of opportunity translational study investigating the use of pre-operative pembrolizumab and chemotherapy or chemoradiotherapy in non-metastatic colorectal cancer.
- Trial name
- NCT03984578
- Testing
- CAPEOX, Pembrolizumab, Capecitabine/ 5-FU
- Where
- 3 sites in Singapore
- Volunteers
- 33 people
- Sponsor
- National Cancer Centre, Singapore
Dengue
Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002)
The purpose of this study was to demonstrate that V181 is safe and well tolerated and elicits an immune response that is non-inferior to that of Butantan - DV at Day 28 post-vaccination in adults 18 to 50 years of age in Brazil.
- Trial name
- NCT05710224
- Testing
- V181, Butantan - DV
- Where
- 14 sites in Brazil
- Volunteers
- 1,364 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Schizophrenia
CAE for Poorly Adherent Individuals With Schizophrenia
This project aims to evaluate the feasibility, acceptability and preliminary efficacy of remotely delivered CAE among patients with schizophrenia (CAE-S).
- Trial name
- CAE-S (NCT06061952)
- Testing
- Customized Adherence Enhancement for Schizophrenia (CAE-S), Enhanced Treatment as Usual (eTAU)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University Hospitals Cleveland Medical Center
Non-Small Cell Lung Cancer, Colorectal Cancer
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa in combination with pembrolizumab in selected tumors.
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT05256381
- Testing
- Nanrilkefusp Alfa, Pembrolizumab
- Where
- 54 sites in United States, Belgium and 7 more
- Volunteers
- 166 people
- Sponsor
- SOTIO Biotech AG
Tumor, Solid
BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab
Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in combination with Pembrolizumab in Subjects with Advanced Solid Tumors
- Trial name
- EIK1001 (NCT03486301)
- Testing
- BDB001 (EIK1001), Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 87 people
- Sponsor
- Eikon Therapeutics
Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
This phase Ib trial studies how well pembrolizumab works with combination chemotherapy in treating participants with small cell/neuroendocrine cancers of the urothelium or prostate that has spread to nearby tissue or lymph nodes…
- Conditions
- Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma
- Trial name
- NCT03582475
- Testing
- Carboplatin, Cisplatin, Docetaxel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Jonsson Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.